Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Commentary|Articles|October 8, 2026
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
Author(s)OncLive Staff
Fact checked by: Caroline Seymour
Advertisement
Advertisement
Brain MRI surveillance without prophylactic cranial irradiation (PCI) in the phase 3 MAVERICK trial (NCT04155034); the B7-H3–directed antibody-drug conjugates (ADCs) tambotatug pelitecan (tam-peli; YL201) and risvutatug rezetecan (ris-rez; HS-20093/GSK5764227) in the phase 3 TAISHAN-302 (NCT06612151) and ARTEMIS-008 (NCT06498479) trials; pumitamig plus elfetabart drozuntecan (elfe-D) in the phase 1b/2 BNT324-01 trial (NCT06892548); and 8-year overall survival (OS) data with adjuvant osimertinib (Tagrisso) from the phase 3 ADAURA trial (NCT02511106) were among the most closely watched
Related to this article
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Advertisement
Advertisement